Meeting
2011 ASCO Annual Meeting
The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts).
Authors
M. Y. Al-Marrawi
Cleveland Clinic Foundation, Cleveland, OH
M. Y. Al-Marrawi , B. I. Rini , L. C. Harshman , G. A. Bjarnason , L. Wood , U. N. Vaishampayan , M. J. MacKenzie , J. J. Knox , N. Agarwal , C. K. Kollmannsberger , M. Tan , S. Y. Rha , F. Donskov , S. A. North , T. K. Choueiri , D. Y. C. Heng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4555)
Abstract #
4555
Poster Bd #
10
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Duration of targeted therapy in metastatic renal cell carcinoma patients with ECOG PS>2.
First Author: Ilya Tsimafeyeu
Poster
2012 Genitourinary Cancers Symposium
Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
First Author: Jiahuai Tan
Poster
2016 ASCO Annual Meeting
Association of high cost sharing and target therapy initiation among Medicare patients with metastatic renal cell carcinoma.
First Author: Pengxiang Li
Poster
2016 Genitourinary Cancers Symposium
RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.
First Author: Thomas Cosgriff